ArticleBMC cancer2026
Phosphoinositide metabolism-related prognostic genes and their prognostic value in cervical cancer: an investigation based on transcriptome, single-cell analyses and verification.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CESC) is a major gynecological malignancy, and abnormalities in phosphoinositide metabolism (PPM) are closely linked to tumor progression. This study aimed to screen phosphoinositide metabolism-related genes (PPM-RGs) with prognostic value for CESC and explore their molecular mechanisms and clinical significance.
methodsCESC transcriptomic datasets and PPM-RGs were retrieved from public databases. Differentially expressed genes were intersected with PPM-RGs to obtain candidate genes. Prognostic genes were screened via univariate Cox regression and proportional hazards assumption test, and a risk model was constructed using random survival forest (RSF). Independent prognostic analysis and nomogram establishment were performed, followed by pathway enrichment, immune infiltration, somatic mutation and single-cell analyses to characterize the tumor microenvironment. Immunohistochemical staining was used to verify the protein expression of key genes in CESC tissues.
resultsTwenty candidate genes were initially identified, and two protective prognostic genes VAC14 and INPP5K were finally determined. The risk model showed favorable predictive performance with area under the curve (AUC) over 0.7, and high-risk patients had poorer survival. The nomogram combining risk score and M stage presented high accuracy. The high-risk group exhibited distinct pathway enrichment, altered immune infiltration and low somatic mutation rates. Monocytes were identified as potential key cells with impaired communication and differentiation in CESC. Immunohistochemistry confirmed downregulated expression of the two genes in CESC epithelial cells.
conclusionVAC14 and INPP5K were PPM-related prognostic genes for CESC. Monocytes played critical roles in CESC progression. The risk model and nomogram aided prognosis prediction, providing new insights for CESC treatment.
Indexed as
Identifiers
42420905What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.